Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03712852 |
Other study ID # |
16102018 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
October 20, 2018 |
Est. completion date |
July 30, 2019 |
Study information
Verified date |
November 2022 |
Source |
G. d'Annunzio University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Gingival thickness plays a key role not only in the etiology but also in the treatment of
gingival recessions. a thin marginal tissue lining the hard periodontal tissues seems to be
one of the main risk factor for the onset of gingival recession ; more recently, authors
reported that as the gingival thickness decreases, the gingival recession severity increases
. When gingival inflammation occurs, if the tissue is thin the consequent destruction can
quickly produce a gingival recession (GR) .
When treating a gingival recession, the clinician should aim not only to completely cover the
exposed root surface but also to prevent a future recession recurrence Currently, CAF
associated with graft is considered as the gold standard for exposed root coverage; this
technique has demonstrated high rates in gingival recession reduction and positive
predictability in obtaining complete root coverage . However, some disadvantages about this
surgical approach can be easily highlighted: patients experience more discomfort, longer
chair-time it's necessary and a second wound area is created . On the other hand, CAF
procedure alone does not require a second surgical site, with better post-operative course,
also reducing the surgical time. However, long term-studies report lower probability of
complete root coverage when using the CAF technique without a simultaneous increase of the
gingival thickness as compared to CAF+graft treatment.
In this scenario, The Platelet rich fibrin (PRF) could be a valuable alternative treatment of
gingival defects. It's a platelet concentrate, obtained by a fast and simple procedure that
does not require anticoagulant and bovine thrombin . It can also be categorized as a live
tissue thanks to platelets, leukocytes, growth factors and stem cells trapped in a
polymerized fibrin mesh. PRF is used in various fields of regenerative medicine; It promotes
stabilization and revascularization of the flaps, contributes to soft tissue wound healing
and reduces post-operative discomfort.
The purpose of this clinical study will be to determine if the combination of platelet rich
fibrine membrane with a modified coronally advanced flap (MCAF) improved the gingival biotype
compared to CAF + graft or CAF alone.
Description:
This prospective, randomized and controlled clinical trial will compare three modalities of
treatment of Miller's class I-II recession: CAF with PRF versus CAF with Sub-epithelial
tissue graft (SCTG) versus CAF. From each patient a single recession on a single tooth
located in the upper arches will be selected. Clinical parameters will be evaluated at
base-line and after 6 months.
The protocol is approved by the "G. D'Annunzio" University Ethical Committee. This study is
in accordance with the Declaration of Helsinki of 1975. Patients will be recruited from the
Unit of Periodontology, Department of Medical, Oral and Biotechnological Sciences, "G.
D'Annunzio" University of Chieti-Pescara, Italy. All the volunteer candidates will sign a
written informed consent.
The trial director will be responsible for randomly assigning patients to treatment after
enrollment and will not involve with the clinical interventions or the study measurements. A
computer-generated table will be used to make the random assignment, known only to the trial
director. An opaque envelope will conceal group allocation and will be opened just before the
intervention surgery. Matching between group and treatment will be performed by a figure
extraneous to the experimentation, responsible even for keeping and breaking the blinding,
and known only to him.
Patients and examiners will be masked to group membership; clinical examiners will be blinded
to each other. The study analyst will be also blind to group membership. The analyst will
receive the data by groups labeled as A and B. The blind will not be broken until after study
completion.
At baseline and 6 months after surgery, the following clinical measurements will be recorded
on the mid-buccal point of exposed root surface: Gingival thickness (GT) will be determined
using a stent at a mid-buccal location about 1 mm apical to the pocket depth (PD) level with
a #15 endodontic reamer with a silicon disk stop. The soft tissue will be gently pierced at a
90° angle, until hard tissue will be felt. Once the silicon disk will be in contact with the
soft tissue surface, it will be fixed by a drop of cyanoacrylate adhesive. After the careful
removal of the reamer, the distance between the reamer tip and the stop will be measured with
a calliper accurate to the nearest 0.1 mm. The other measurements will be taken with a
periodontal probe and will be recorded to the nearest millimetre as follows: Gingival
recession (GR) will be measured as the distance from the cement-enamel junction (CEJ) to the
mid-buccal point of the gingival margin. PD and Clinical attachment level (CAL) will be
measured as the distance between the bottom of the pocket and the gingival margin and CEJ,
respectively. Keratinized tissue (KT) will be recorded from the mid-buccal point of the
gingival margin to the mucogingival junction.
Patient morbidity will be evaluated with a visual analogue scale (VAS). Root coverage
esthetic score (RES) (Cairo et al., 2009) will be used for assessing aesthetic outcomes of
root coverage procedures.
All clinical parameters will be measured by the same investigator. To avoid a calibration
probing bias, 60 recession defects will be measured twice within 72 hours. When 90% of the
measurements of Gingival thickness will be within 0.3 mm and within 0.5 mm for measurements
of GR , calibration will be successfully accepted.
30 ml of blood samples will be collected in 10-ml tubes without anticoagulant and promptly
centrifuged at 3,000 revolutions per minute for 10 minutes. The acellular plasma formed in
the upper layer will be washed out. The clot, positioned in the middle of the vial, will be
cut off from the lower red corpuscles part. Each PRF clot will be folded onto itself in order
to double the thickness, and two membranes placed one over the other (quadruple L-PRF layer)
represented the L-PRF graft.
The connective tissue graft will be harvested from the palatal area on the opposite side of
the gingival defect according to Zucchelli et al12. Briefly, two horizontal and two vertical
incisions will delimitate the donor area. The graft will be separated from the underlying
tissues by the scalpel's blade oriented parallel to the palatal surface to obtain an about 2
mm thick graft. Then, the graft will be de-epithelialized by a 15c blade and the fatty tissue
will be eliminated until obtaining a graft with a thickness of about 1,5 mm. measured by a
standard caliper.
Exposed and intrasulcular root surface will be accurately scaled using curettes. A modified
coronally advanced flap technique (MCAF) will be used to treat the recession defect. The flap
will be elevated as follows: an intrasulcular incision will be performed around the selected
tooth, the incision moves on contiguous papillae area, avoiding the gingival margin of
adjacent teeth. From each side, from coronal to apical, an oblique incision will be carried
out. A split-full-split dissection will be undertaken until the CEJ could be passively cover
by the flap. Both papillae will be de-epithelialized. The PRFs and the SCTGs will be placed
over the exposed root surface of the Test group and Control 1 group respectively. The
gingival defect will be fully lined by grafts that mildly cover the neighbouring sub-papillae
areas. The grafts will be fixed applying suture to the periosteum below. In each group, flap
will be coronally positioned and sutured over the enamel in a tension-free position.
All patients will receive 2 g/day amoxicillin+clavulanic acid for 6 days for post-operative
infection prevention; 400 mg of oral ibuprofen, twice daily, will control the pain; 0.12%
chlorhexidine rinses, twice daily for 3 weeks, will be prescribe to the patients. Sutures
will be removed after 14 days. Only 2-4 weeks after sutures removal, respectively, cautious
brushing by a soft toothbrush and interdental brushing will be recommend; meantime, the
patients use a 1% chlorhexidine gel twice daily. Weekly supra-gingival professional hygiene
and motivational reinforcement will be administer to the patients for 6 weeks.